REGINA DIZON: Open Payments
NPI 1609538040 · NEWPORT BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,422 in 31 payments from 11 companies in 2025. Trend: 2023 $442 · 2024 $1,620 · 2025 $1,422
Food & beverage: $1,422
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 10 | $408 |
| Alkermes, Inc. | 3 | $267 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $139 |
| Neurocrine BioSciences, Inc. | 4 | $133 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| E.R. Squibb & Sons, L.L.C. | 4 | $93 |
| Indivior Inc. | 3 | $68 |
| OWP Pharmaceuticals, Inc. | 1 | $23 |
| Braeburn Inc. | 1 | $22 |
Products named: HETLIOZ, FANAPT, ARISTADA, CAPLYTA, INGREZZA, Qelbree, Auvelity, LYBALVI.
Industry payments across CA — which companies pay providers there.
